Home | Articles
Published on:August 2021
Indian Journal of Pharmaceutical Education and Research, 2021; 55(3):738-747
Original Article | doi:10.5530/ijper.55.3.146

Coordinated Androgen and Estrogen-receptor microRNA 26 Directive in Breast and Prostate Tumour

Authors and affiliation (s):

Santosh Fattepur1,*, Kiran Chanabasappa Nilugal1, Ibrahim Abdullah1, Nagaraja Sreeharsha2,3, Md. Khalid Anwer4, Syed Mohammed Basheeruddin Asdaq5

1School of Pharmacy, Management and Science University, Seksyen 13, Shah Alam, Selangor, MALAYSIA.

2Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa, SAUDI ARABIA.

3Department of Pharmaceutics, Vidya Siri College of Pharmacy, Bengaluru, Karnataka, INDIA.

4Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Alkharj, SAUDI ARABIA.

5Department of Pharmacology, College of Pharmacy, AlMaarefa University, Riyadh, SAUDI ARABIA.


MiR-26 is a miRNA tumour suppressor that is frequently dysregulated in many tumour tissues and lines of tumour cells. Androgen and Estrogen receptor (AR & ER) were evolving as a target to examine among hormone proteins since it appears to show a part at numerous phases of growth of breast and prostate cancers. For that kind of reason, AR and ER are becoming very relevant in recent times. Although its position remains problematic in medical care, the various finding had demonstrated a link among microRNAs 26, a group of receptors of genetic expression, and cancer (AR & ER), but there is still little evidence for the association among BC and PC miRNAs. The major goal of our study is to deliver AR and ER pathways involved in the development of microRNAs 26. Moreover, the functional and structural analysis of microRNAs 26 concerning cancer and non-cancerous cells were also discussed briefly. Additionally, the gene for post-transcriptional regulatory functions in breast and prostate cancer of different dysfunctional miRNAs 26 and their medicinal properties were also presented.

Keywords: Breast cancer, Prostate cancer, microRNA 26, Androgen receptor (AR), Estrogen receptor (ER).



Impact Factor

IJPER - An Official Publication of Association of Pharmaceutical Teachers of India is pleased to announce continued growth in the 2019 Release of Journal Citation Reports (source: 2018 Web of Science Data).


Impact Factor® as reported in the 2018 Journal Citation Reports® (Clarivate Analytics, 2019): 0.425

The Official Journal of Association of Pharmaceutical Teachers of India (APTI)
(Registered under Registration of Societies Act XXI of 1860 No. 122 of 1966-1967, Lucknow)

Indian Journal of Pharmaceutical Education and Research (IJPER) [ISSN-0019-5464] is the official journal of Association of Pharmaceutical Teachers of India (APTI) and is being published since 1967.


IJPER uses reference linking service using Digital Object Identifiers (DOI) by Crossref. Articles from the year 2013 are being assigned DOIs for its permanent URLs